Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

263
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
263
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

507
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
507
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

36
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
36
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.5K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.5K
Phase I Reactions: Reductive Reactions01:27

Phase I Reactions: Reductive Reactions

341
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
341

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease.

Nature communications·2026
Same author

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Nature medicine·2026
Same author

Fellows' Corner.

Hepatology (Baltimore, Md.)·2026
Same author

Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction.

Drug design, development and therapy·2026
Same author

A reasonably likely surrogate endpoint for metabolic dysfunction-associated steatohepatitis.

Nature medicine·2026
Same author

Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH.

Hepatology communications·2026

Related Experiment Videos

New drugs for NASH.

Somaya A M Albhaisi1, Arun J Sanyal2

  • 1Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.

Liver International : Official Journal of the International Association for the Study of the Liver
|June 22, 2021
PubMed
Summary

New drugs are urgently needed for non-alcoholic steatohepatitis (NASH), a growing cause of liver failure. This review covers promising phase 2 drug study results and ongoing clinical trials for NASH treatments.

Keywords:
clinical trialsdrug therapyfatty livernon-alcoholic steatohepatitispharmacotherapy

Related Experiment Videos

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Background:

  • Non-alcoholic steatohepatitis (NASH) involves liver inflammation and injury, often progressing to cirrhosis.
  • NASH is a leading cause of liver failure and transplantation in the US, linked to metabolic conditions.
  • Current treatments focus on lifestyle changes, which are often insufficient for advanced disease.

Purpose of the Study:

  • To review pivotal phase 2 clinical trial results for NASH pharmacotherapies.
  • To outline key ongoing clinical trials investigating novel NASH drug candidates.
  • To highlight the urgent need for effective pharmacological treatments for NASH.

Main Methods:

  • Summarized data from completed phase 2 studies of NASH drugs.
  • Compiled information on active clinical trials for NASH therapies.
  • Focused on drugs targeting specific pathological pathways in NASH.

Main Results:

  • Several drug candidates have shown promising results in phase 2 trials.
  • Numerous novel agents are currently in active clinical development for NASH.
  • The review details trial data for drugs targeting diverse NASH mechanisms.

Conclusions:

  • Effective pharmacotherapy is critical for managing NASH, especially in advanced stages.
  • The pipeline of NASH drug development is robust, offering future treatment options.
  • Continued research and clinical trials are essential to address the growing NASH epidemic.